ATE501125T1 - Verfahren zur herstellung des calciumsalzes von rosuvastatin - Google Patents

Verfahren zur herstellung des calciumsalzes von rosuvastatin

Info

Publication number
ATE501125T1
ATE501125T1 AT03784274T AT03784274T ATE501125T1 AT E501125 T1 ATE501125 T1 AT E501125T1 AT 03784274 T AT03784274 T AT 03784274T AT 03784274 T AT03784274 T AT 03784274T AT E501125 T1 ATE501125 T1 AT E501125T1
Authority
AT
Austria
Prior art keywords
rosuvastatin
producing
calcium salt
calcium
salt
Prior art date
Application number
AT03784274T
Other languages
English (en)
Inventor
John Horbury
Nigel Taylor
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE501125(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Application granted granted Critical
Publication of ATE501125T1 publication Critical patent/ATE501125T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03784274T 2002-08-13 2003-08-07 Verfahren zur herstellung des calciumsalzes von rosuvastatin ATE501125T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0218781.3A GB0218781D0 (en) 2002-08-13 2002-08-13 Chemical process
PCT/GB2003/003463 WO2004014872A1 (en) 2002-08-13 2003-08-07 Process for preparing the calcium salt of rosuvastatin

Publications (1)

Publication Number Publication Date
ATE501125T1 true ATE501125T1 (de) 2011-03-15

Family

ID=9942204

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03784274T ATE501125T1 (de) 2002-08-13 2003-08-07 Verfahren zur herstellung des calciumsalzes von rosuvastatin

Country Status (30)

Country Link
US (2) US7511140B2 (de)
EP (1) EP1539711B1 (de)
JP (1) JP4588446B2 (de)
KR (1) KR101325827B1 (de)
CN (1) CN100361979C (de)
AR (1) AR040868A1 (de)
AT (1) ATE501125T1 (de)
AU (1) AU2003251369B2 (de)
BR (1) BR0313394A (de)
CA (1) CA2495296C (de)
CY (1) CY1112412T1 (de)
DE (1) DE60336326D1 (de)
DK (1) DK1539711T3 (de)
ES (1) ES2361009T3 (de)
GB (1) GB0218781D0 (de)
HK (1) HK1082735A1 (de)
IL (1) IL166626A (de)
IS (1) IS7728A (de)
MX (1) MXPA05001582A (de)
MY (1) MY135301A (de)
NO (1) NO329439B1 (de)
NZ (1) NZ538070A (de)
PL (1) PL375296A1 (de)
PT (1) PT1539711E (de)
RU (1) RU2326871C2 (de)
SI (1) SI1539711T1 (de)
TW (1) TWI316058B (de)
UA (1) UA83805C2 (de)
WO (1) WO2004014872A1 (de)
ZA (1) ZA200500745B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
EP1417180B1 (de) 2001-07-13 2006-12-27 AstraZeneca UK Limited Herstellung von aminopyrimidinverbindungen
EP1323717A1 (de) 2001-12-27 2003-07-02 Dsm N.V. Prozess für die Herstellung von 2-(6-Substituierten-1,3-Dioxan-4-yl) Essigsäure Derivaten
EP1375493A1 (de) 2002-06-17 2004-01-02 Dsm N.V. Verfahren zur Herstellung von Dioxanessigsäureester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
AU2003288443B2 (en) 2002-12-16 2007-10-25 Astrazeneka Uk Limited Process for the preparation of pyrimidine compounds
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005023778A2 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
CA2546894C (en) 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
EP1737828A1 (de) * 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Amorphe magnesiumsalze von rosuvastatin
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
JP2007508379A (ja) 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
WO2006035277A2 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
US7985418B2 (en) * 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
WO2006066512A1 (fr) * 2004-12-23 2006-06-29 Zhejiang Hisun Pharma. Co., Ltd Dérivés de pyrimidinone, leur synthèse et leurs applications
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2594692A1 (en) * 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
TWI353981B (en) 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
JP5146965B2 (ja) 2005-06-24 2013-02-20 レツク・フアーマシユーテイカルズ・デー・デー 不純物を含まない非晶質ロスバスタチンカルシウムの調製方法
SI1915349T1 (sl) 2005-06-24 2016-05-31 Lek Pharmaceuticals D.D. Postopek za pripravo čistega amorfnega rosuvastatin kalcija
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
RU2008108078A (ru) * 2005-08-04 2009-09-10 Трансформ Фармасьютикалз, Инк. (Us) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
TW200800918A (en) 2005-08-16 2008-01-01 Teva Pharma Rosuvastatin calcium with a low salt content
JP2008515931A (ja) 2005-08-16 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 結晶形ロスバスタチン中間体
HUE026628T2 (en) 2005-09-15 2016-06-28 Genzyme Corp Pouches for amine polymers
WO2007125547A2 (en) 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2079712A2 (de) * 2006-10-31 2009-07-22 Aurobindo Pharma Limited Verbessertes verfahren zur herstellung von rosuvastatin-kalzium
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
WO2008072078A1 (en) 2006-12-13 2008-06-19 Aurobindo Pharma Limited An improved process for preparing rosuvastatin caclium
US8212035B2 (en) 2007-02-08 2012-07-03 Aurobindo Pharma Ltd. Process for preparation of rosuvastatin calcium field of the invention
JP2010533188A (ja) * 2007-07-12 2010-10-21 テバ ファーマシューティカル インダストリーズ リミティド ロバスタチン中間体及びその製法
HU230637B1 (hu) * 2007-10-12 2017-05-29 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin intermedierek előállítására
HU230981B1 (hu) * 2007-10-12 2019-08-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin só előállítására
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
WO2010035284A2 (en) * 2008-09-26 2010-04-01 Matrix Laboratories Ltd An improved process for the preparation of rosuvastatin calcium
EP2350025A1 (de) * 2008-09-30 2011-08-03 Aurobindo Pharma Limited Verbessertes verfahren zur herstellung von pyrimdinpropenaldehyd
EA021942B1 (ru) 2009-01-15 2015-10-30 Эгиш Дьёдьсердьяр Зрт. Способ изготовления солей розувастатина
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
EP2526099B1 (de) 2010-01-18 2016-03-30 MSN Laboratories Limited Verbessertes verfahren zur herstellung von amid-zwischenprodukten und seine anwendung
EP2560970A1 (de) 2010-04-23 2013-02-27 Ranbaxy Laboratories Limited Neue zwischenprodukte zur herstellung von hmg-coa-reduktasehemmern
HU230987B1 (hu) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
EP2978744A1 (de) * 2013-03-29 2016-02-03 DSM Sinochem Pharmaceuticals Netherlands B.V. Aminsalze von pitavastatin und rosuvastatin
TWM477638U (zh) * 2013-12-12 2014-05-01 三緯國際立體列印科技股份有限公司 加熱平台與立體列印裝置
MX2019009213A (es) 2017-01-23 2019-09-27 Dong Wha Pharm Co Ltd Formulación compleja que comprende inhibidor de la hmg-coa reductasa y clopidogrel.
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離ｃｄ８＋選擇ｔ細胞的方法
SI26268A (sl) 2021-11-18 2023-05-31 Zupet Rok Postopek za pripravo hidratirane oblike perindopril l-arginina

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US663641A (en) * 1900-10-11 1900-12-11 Charles A Ruebekam Burial-casket.
US4645858A (en) * 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
EP0367895A1 (de) 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl substituierte Hydroxysäuren, Laktone und Ester und diese enthaltende pharmazeutische Zusammenstellungen
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) * 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
SG44830A1 (en) * 1992-07-02 1997-12-19 Hoechst Ag Process for preparing tert-butyl 93R,5S) -6 Hydroxy-3,5-O-Isopropylidene-3, 5-Dihydroxyhexanoate
PL193479B1 (pl) 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
US6278001B1 (en) * 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
DK0907639T3 (da) 1996-06-24 2003-06-23 Novartis Ag Polymorfe forbindelser
KR100672269B1 (ko) * 1998-12-10 2007-01-23 카네카 코포레이션 심바스타틴의 제조 방법
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
DE60023296T2 (de) * 1999-07-13 2006-07-20 Lonza Ag Verfahren zur herstellung von 2-amino-4(4-fluorphenyl)-6-alkylpyrimidin-5-carbonsäureester
AU7717500A (en) 1999-09-30 2001-04-30 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
PT1535613E (pt) 1999-11-17 2010-10-04 Teva Pharma Processo de preparação de uma forma polimórfica de atorvastatina de cálcio
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
CN1468098A (zh) 2000-10-05 2004-01-14 �ݰ¸Ƕ�ҩ�����޹�˾ 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物
NZ526022A (en) 2000-11-16 2005-04-29 Teva Pharma Hydrolysis of [R(R*,R )]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
IN190564B (de) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
US6875867B2 (en) * 2001-06-06 2005-04-05 Bristol-Myers Squibb Company Process for preparing chiral diol sulfones and dihydroxy acid HMG CoA reductase inhibitors
EP1417180B1 (de) * 2001-07-13 2006-12-27 AstraZeneca UK Limited Herstellung von aminopyrimidinverbindungen
SK1402004A3 (sk) * 2001-08-16 2005-01-03 Teva Pharmaceutical Industries Ltd. Spôsob prípravy vápenatých solí statinov
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
CN1545502A (zh) 2001-08-22 2004-11-10 �������⻯ѧƷ�ع����޹�˾ 吲哚衍生物的制备方法
WO2003026573A2 (en) 2001-09-24 2003-04-03 Merck & Co., Inc. Screening and selection methods for statin drug combinations
EP1323717A1 (de) 2001-12-27 2003-07-02 Dsm N.V. Prozess für die Herstellung von 2-(6-Substituierten-1,3-Dioxan-4-yl) Essigsäure Derivaten
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
EP1585736A2 (de) 2002-05-21 2005-10-19 Ranbaxy Laboratories, Ltd. Verfahren zur herstellung von rosuvastatin
EP1375493A1 (de) 2002-06-17 2004-01-02 Dsm N.V. Verfahren zur Herstellung von Dioxanessigsäureester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
ATE501126T1 (de) 2002-12-10 2011-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von rosuvastatin
AU2003288443B2 (en) * 2002-12-16 2007-10-25 Astrazeneka Uk Limited Process for the preparation of pyrimidine compounds
CA2520740C (en) 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
AU2003247327A1 (en) 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1678148A1 (de) 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Verfahren zur herstellung von amorphen rosuvastatin-calcium
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
US7028631B2 (en) * 2003-11-24 2006-04-18 The Boeing Company Gliding submersible transport system
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
CA2546894C (en) 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
EP1697338A2 (de) 2003-12-24 2006-09-06 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von statinen mit hohem syn-zu-anti-verhältnis
CZ200486A3 (cs) 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
EP1737828A1 (de) 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Amorphe magnesiumsalze von rosuvastatin
EP1709008A1 (de) 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salze von hmg-coa-reduktase-inhibitoren und deren verwendung
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
US7161004B2 (en) * 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
JP2007508379A (ja) 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2594692A1 (en) 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
PT1539711E (pt) 2011-05-03
US7511140B2 (en) 2009-03-31
GB0218781D0 (en) 2002-09-18
ES2361009T3 (es) 2011-06-13
KR20050036968A (ko) 2005-04-20
US20060116391A1 (en) 2006-06-01
US7842807B2 (en) 2010-11-30
JP2006500347A (ja) 2006-01-05
MXPA05001582A (es) 2005-04-25
TW200404786A (en) 2004-04-01
EP1539711A1 (de) 2005-06-15
CA2495296C (en) 2011-05-03
RU2005102391A (ru) 2005-10-10
DE60336326D1 (de) 2011-04-21
IL166626A0 (en) 2006-01-15
AR040868A1 (es) 2005-04-20
CN100361979C (zh) 2008-01-16
TWI316058B (en) 2009-10-21
RU2326871C2 (ru) 2008-06-20
AU2003251369A1 (en) 2004-02-25
PL375296A1 (en) 2005-11-28
HK1082735A1 (en) 2006-06-16
IS7728A (is) 2005-03-08
NZ538070A (en) 2006-08-31
MY135301A (en) 2008-03-31
AU2003251369B2 (en) 2007-02-01
ZA200500745B (en) 2006-03-29
DK1539711T3 (da) 2011-05-30
EP1539711B1 (de) 2011-03-09
US20090286819A1 (en) 2009-11-19
SI1539711T1 (sl) 2011-06-30
KR101325827B1 (ko) 2013-11-05
CY1112412T1 (el) 2015-12-09
BR0313394A (pt) 2005-06-21
UA83805C2 (uk) 2008-08-26
IL166626A (en) 2011-09-27
NO329439B1 (no) 2010-10-18
CN1688551A (zh) 2005-10-26
NO20050542L (no) 2005-02-28
CA2495296A1 (en) 2004-02-19
WO2004014872A1 (en) 2004-02-19
JP4588446B2 (ja) 2010-12-01

Similar Documents

Publication Publication Date Title
ATE501125T1 (de) Verfahren zur herstellung des calciumsalzes von rosuvastatin
DE602004026576D1 (de) Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz
DE60323192D1 (de) Verfahren zur Herstellung von Hydroxyalkylstärkederivaten
DE60128723D1 (de) Verfahren zur herstellung von bio-resorbierbaren implantaten
DE502004001613D1 (de) Verfahren zur herstellung von polyamiden
DE60330341D1 (de) Verfahren zur herstellung von wabenstrukturen
DE60225539D1 (de) Verfahren zur kontinuierlichen herstellung von polyarylensulfid
DE60330050D1 (de) Verfahren zur herstellung von pyrimidinverbindungen
DE60204334D1 (de) Verfahren zur herstellung von repaglinide
DE50311721D1 (de) Verfahren zur Herstellung von Aryl-aminopropanolen
DE60234275D1 (de) Verfahren zur herstellung von diglyceriden
DE50303611D1 (de) Verfahren zur herstellung von polyisobuten
ATE424892T1 (de) Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
DE60113157T2 (de) Verbessertes verfahren zur herstellung von simvastatin
DE60322356D1 (de) Verfahren zur herstellung von 2-aminoindanderivaten
DE60309805D1 (de) Kontinuierliches Verfahren zur Herstellung von 3-Methylthiopropanal
DE602004001646D1 (de) Verfahren zur Herstellung von Pyran
DE602004005239D1 (de) Verfahren zur herstellung von tubulininhibitoren
DE602004027840D1 (de) Verfahren zur herstellung von thiazolopyrimidinen
DE60301444T2 (de) Verfahren zur Herstellung von Polyalkylphenoxyaminoalkanen
DE60302979D1 (de) Verfahren zur Herstellung von Epsilon-Caprolactone
DE602004018447D1 (de) Verfahren zur Herstellung von Alkylbenzaldehyden
DE60322872D1 (de) Verfahren zur herstellung von säuresalzen von gemifloxacin
DE60330749D1 (de) Verfahren zur herstellung von 7-alpha-methylsteroide
DE60324881D1 (de) Verfahren zur Herstellung von Polyalkylphenoxyaminoalkanen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1539711

Country of ref document: EP